Stock doesn't offer attractive dividend returns
Good time to consider, as stock is not in overbought zone
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
The company is a preclinical contract research company. It provides preclinical safety assessment services, assessment services for evaluating the safety of the active pharmaceutical ingredients (API), etc.
Customise key metrics, see detailed forecasts, download stock data and more
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant